trending Market Intelligence /marketintelligence/en/news-insights/trending/UFLpOuKnWhYtqe-qGmbxBQ2 content esgSubNav
In This List

Stemline Therapeutics to raise $76.3M to commercialize cancer drug Elzonris

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Stemline Therapeutics to raise $76.3M to commercialize cancer drug Elzonris

Stemline Therapeutics Inc. priced an underwritten public offering to raise about $76.3 million.

The New York-based cancer drug developer will sell 5 million shares at $15.25 apiece to raise the amount, which will be used primarily for commercial activities of Elzonris, a treatment for blastic plasmacytoid dendritic cell neoplasm, a rare blood disease.

J.P. Morgan Securities LLC and Cowen and Co. LLC are the joint book-running managers for the offering, while Cantor Fitzgerald & Co., Ladenburg Thalmann & Co. Inc. and H.C. Wainwright & Co. LLC are acting as co-lead managers. ThinkEquity of Fordham Financial Management Inc., Alliance Global Partners and Aegis Capital Corp. are acting as co-managers for the offering.

The underwriters can purchase up to an additional 750,000 shares from the company. The offering is expected to close on or around Aug. 13.